Speaker: James E. Cassat, MD, PhD, Associate Director, Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4); Associate Professor of Pediatrics, Pathology, Microbiology, and Immunology; and BME
The Cancer Network featured an interview with Dr. Keith Wilson which was published in the journal Oncology.
" Dr. Wilson and his colleagues recently published a study showing that a chemopreventive drug can also act directly on Helicobacter pylori (H. pylori), a bacterium that is the primary cause of gastric cancer."
Keith Wilson, MD, VUMC’s principal investigator and director of the Vanderbilt Center for Mucosal Inflammation and Cancer, said the effort will help bridge the bench-to-bedside gap between discovery science and improving treatment options for patients. “This is a good beginning,” he said, “the tip of the iceberg.”
Wilson and his colleagues began using cell cultures to explore the enzymatic pathways that produce nitric oxide and alternative products. Their studies led them to molecules called polyamines, which are produced by the enzyme ornithine decarboxylase (ODC) and which have been shown to be both detrimental and beneficial to cells, depending on the context.